How do I diagnose and manage a patient with suspected mumps, including isolation, supportive care, analgesic dosing, and vaccination or post‑exposure prophylaxis recommendations?

Diagnosis and Management of Suspected Mumps

Immediate Diagnostic Approach

Laboratory confirmation is mandatory for all suspected mumps cases, as clinical diagnosis alone misdiagnoses approximately one-third of patients. 1

Clinical Presentation to Recognize

• Classic features: Bilateral parotid swelling lasting ≥2 days without purulent discharge from Stensen's duct 1
• Distinguish from bacterial sialadenitis: Bacterial causes typically present with unilateral swelling, purulent discharge, fever, and predisposing factors like dehydration or ductal obstruction 1
• Prodromal symptoms: Fever, headache, and nonspecific upper respiratory symptoms may precede parotitis by several days 2, 3
• Important caveat: 20-40% of mumps infections are asymptomatic, and parotitis is not present in all cases 4, 5

Laboratory Testing Protocol

Obtain these tests within 9 days of symptom onset: 1

• Primary test: Mumps-specific IgM antibody detection 4, 1
• Viral PCR from parotid duct swab: Collect after massaging the parotid gland for 30 seconds; this is the most sensitive test early in illness 4, 1
• Alternative specimens: Buccal swabs for viral culture or PCR; urine PCR remains positive for at least 5 days after oral detection but is less sensitive 4, 1
• Acute and convalescent serology: Significant rise in mumps IgG antibody titers between specimens collected 10-30 days apart confirms diagnosis 4

Critical pitfall: Previously vaccinated patients may not develop detectable IgM response, making viral PCR essential in this population 4

Mandatory additional test: HIV testing for all patients with parotitis, regardless of perceived risk factors, as HIV can present with parotid swelling 1

Case Classification

• Confirmed case: Meets laboratory criteria OR meets clinical definition and is epidemiologically linked to a confirmed/probable case 1
• Probable case: Meets clinical definition but not epidemiologically linked and has noncontributory or no laboratory testing 1
• Two epidemiologically linked probable cases are considered confirmed even without laboratory confirmation 1

---

Isolation and Infection Control

Implement droplet precautions and isolation for 5 days after parotitis onset immediately upon suspicion of mumps. 6, 3

Isolation Specifications

• Duration: 5 days after onset of parotitis (updated from previous 9-day recommendation) 3
• Precautions: Standard precautions plus droplet precautions 3
• Infectious period: Patients are contagious from 7 days before through 8 days after parotitis onset, but isolation for 5 days after onset balances infection control with compliance 6, 3
• Transmission route: Respiratory droplets and direct contact with saliva 6, 2

Healthcare Setting Considerations

• Do not assign susceptible staff to care for mumps patients 4
• Implement contact investigations to identify exposed persons 4
• Healthcare-associated transmission, though infrequent, can result in significant economic costs and staff furlough 4

---

Supportive Care and Symptom Management

Treatment is entirely supportive, as no specific antiviral therapy exists for mumps. 6, 2

Analgesic and Antipyretic Dosing

• Acetaminophen or NSAIDs for fever, headache, and parotid gland pain 6
• Ensure adequate fluid intake, as parotitis makes swallowing uncomfortable 6

Monitoring for Complications

Watch for these serious complications requiring immediate evaluation:

• Aseptic meningitis (4-6% of cases): Severe headache, neck stiffness, photophobia, altered mental status 6, 7
• Orchitis (20-30% of postpubertal males): Testicular pain and swelling; sterility is rare 4, 6
• Pancreatitis: Severe abdominal pain, nausea, vomiting 6
• Encephalitis: Seizures, paralysis, cranial nerve palsies 6, 7
• Sensorineural deafness: Can be sudden and permanent; occurs in approximately 1 per 20,000 cases 4, 6
• Oophoritis: Can occur in adult women 5

---

Vaccination and Post-Exposure Prophylaxis

Assessing Immunity Status

Acceptable evidence of mumps immunity includes: 4

• Documentation of two doses of MMR vaccine (first dose on/after first birthday, second dose ≥28 days later) 4
• Laboratory evidence of immunity (any mumps IgG antibody level above standard positive cutoff) 8
• Birth before 1957 (though healthcare facilities should consider vaccinating these individuals during outbreaks) 4
• Physician-diagnosed mumps disease 4

Post-Exposure Vaccination Recommendations

MMR vaccine administered within 72 hours of exposure may prevent or modify disease, though evidence is stronger for measles than mumps. 4

• Vaccinate susceptible exposed persons even if beyond the 72-hour window, as it provides protection against future exposure 4
• No contraindication to vaccinating persons already immune to mumps through previous vaccination or natural disease 4
• Healthcare workers born before 1957: Consider two doses of MMR during outbreaks if they lack laboratory evidence of immunity 4

Vaccine Effectiveness Context

• One-dose effectiveness: 80-85% (range 75-91%) 4
• Two-dose effectiveness: 79-95% 4
• Breakthrough infections can occur in highly vaccinated populations, particularly in crowded settings like colleges 4, 9
• Antibody levels wane over time, but clinical significance is unclear 4

Contraindications to MMR Vaccination

• Pregnancy (defer until after delivery) 4
• Immunocompromised states: immune deficiency diseases, leukemia, lymphoma, generalized malignancy 4
• Immunosuppressive therapy: corticosteroids, alkylating drugs, antimetabolites, radiation 4
• Recent immune globulin or blood product administration (defer vaccine for 6 weeks to 3 months) 4
• Anaphylactic reaction to neomycin 4

---

Special Populations

Healthcare Workers

• Two doses of MMR required for those born during or after 1957 without other evidence of immunity 4
• Serologic screening before vaccination is not necessary unless cost-effective 4
• During outbreaks, vaccinate unvaccinated workers born before 1957 who lack serologic evidence of immunity 4

Pregnant Women

• Do not administer MMR vaccine during pregnancy 4
• Rubella immunity is particularly important for women of childbearing age 4

International Travelers

• Ensure two doses of MMR before departure for persons ≥12 months old 4
• Infants 6-11 months traveling internationally should receive monovalent measles vaccine (or MMR if monovalent unavailable) before departure 4

---

Reporting Requirements

Mumps is reportable in most states; verify local reporting regulations and procedures. 2